EICHOR
● Recruiting
Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma
Condition: Signet Ring Cell Gastric Adenocarcinoma · Sponsor: University Hospital, Lille
About this study
The ADCI 002 trial is a large multicenter phase II-III prospective randomized controlled trial comparing primary surgery versus primary chemotherapy followed by surgery in patients with a resectable signet ring cell gastric adenocarcinoma
This description comes directly from the study's public registry record.
Talk to the study team
Guillaume Piessen, MD,PhD · +33320444407 · guillaume.piessen@chru-lille.fr
Always discuss trial participation with your own doctor first.
Locations (1)
| General and digestive surgical department, Claude Huriez Hospital, University Hospital | Lille, France | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01717924